Physician profile
Robert W Jacey
NPI 1043291511
$713.39
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.51 · 2020: $20.58 · 2021: $290 · 2022: $193 · 2023: $114 · 2024: $78.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $114.52 | 2021-2023 | Acthar |
| Allergan, INC. | $114.15 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $109.56 | 2021 | |
| Sun Pharmaceutical Industries INC. | $68.83 | 2020-2022 | |
| Oyster Point Pharma, INC. | $57.38 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $35.01 | 2021-2023 | |
| Kala Pharmaceuticals, INC. | $30.08 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $28.56 | 2021-2022 | |
| Alcon Vision LLC | $24.44 | 2024 | Hydrus Microstent |
| Abbvie INC. | $20.90 | 2022 | |
| Horizon Therapeutics Plc | $20.70 | 2023 | Tepezza |
| Sight Sciences, INC. | $20.66 | 2023 | Tearcare System |
| Harrow Eye, LLC | $20.37 | 2024 | Vevye |
| Rxsight INC | $19.75 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Aerie Pharmaceuticals, INC. | $14.79 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $13.69 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jacey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.